6 Works

Data from: On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials

Matthieu Roustit, Joris Giai, Olivier Gaget, Charles Khouri, Myriam Mouhib, Adrien Lotito, Sophie Blaise, Christophe Seinturier, Fabien Subtil, Adeline Paris, Claire Cracowski, Bernard Imbert, Patrick Carpentier, Sunita Vohra & Jean-Luc Cracowski
Background: Treatment of Raynaud phenomenon (RP) with phosphodiesterase-5 inhibitors has shown moderate efficacy. Adverse effects decrease the risk–benefit profile of these drugs, and patients may not be willing to receive long-term treatment. On-demand single doses before or during exposure to cold may be a good alternative. Objective: To assess the efficacy and safety of on-demand sildenafil in RP. Design: Series of randomized, double-blind, n-of-1 trials. (ClinicalTrials.gov: NCT02050360). Setting: Outpatients at a French university hospital. Participants:...

Effects of high and low-efficacy therapy in secondary progressive multiple sclerosis

Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach, Francois Grand'Maison, Jeannette Lechner-Scott, Charles Malpas, Helmut Butzkueven, Sandra Vukusic … & Tomas Kalincik
Objective: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactive secondary progressive multiple sclerosis (SPMS) after accounting for therapeutic lag. Methods: Patients treated with high- (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low-efficacy (interferon β, glatiramer acetate, teriflunomide) therapies after SPMS onset were selected from MSBase and OFSEP, two large observational cohorts. Therapeutic lag was estimated for each patient based on their demographic and clinical characteristics....

Dormoy al - suppl Table 1.pdf

Alexandre Dormoy, Magalie Haissaguerre, Géraldine VITELLIUS, Christine Do Cao, Aurore Geslot, Hélène Lasolle, Delphine Drui, Sylvie Salenave, Marie Puerto, Hélène Du Boullay, Anne Mayer, Claire Laurent, Olivier Chabre, Frédéric Castinetti, Yves Reznik, Eric Baudin, Gérald Raverot, Antoine Tabarin & Jacques Young
Prospective studies have demonstrated the efficacy of osilodrostat in Cushing's disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing’s syndrome/ectopic ACTH syndrome (PNCS/EAS). Objective: Evaluate in France the real-world efficacy and safety of osilodrostat in PNCS/EAS. Patients: 33 patients with PNCS/EAS with intense/severe hypercortisolism.

Dormoy al - suppl Table 1.pdf

Alexandre Dormoy, Magalie Haissaguerre, Géraldine VITELLIUS, Christine Do Cao, Aurore Geslot, Hélène Lasolle, Delphine Drui, Sylvie Salenave, Marie Puerto, Hélène Du Boullay, Anne Mayer, Claire Laurent, Olivier Chabre, Frédéric Castinetti, Yves Reznik, Eric Baudin, Gérald Raverot, Antoine Tabarin & Jacques Young
Prospective studies have demonstrated the efficacy of osilodrostat in Cushing's disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing’s syndrome/ectopic ACTH syndrome (PNCS/EAS). Objective: Evaluate in France the real-world efficacy and safety of osilodrostat in PNCS/EAS. Patients: 33 patients with PNCS/EAS with intense/severe hypercortisolism.

Dormoy al - suppl Table 1.pdf

Alexandre Dormoy, Magalie Haissaguerre, Géraldine VITELLIUS, Christine Do Cao, Aurore Geslot, Hélène Lasolle, Delphine Drui, Sylvie Salenave, Marie Puerto, Hélène Du Boullay, Anne Mayer, Claire Laurent, Olivier Chabre, Frédéric Castinetti, Yves Reznik, Eric Baudin, Gérald Raverot, Antoine Tabarin & Jacques Young
Prospective studies have demonstrated the efficacy of osilodrostat in Cushing's disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing’s syndrome/ectopic ACTH syndrome (PNCS/EAS). Objective: Evaluate in France the real-world efficacy and safety of osilodrostat in PNCS/EAS. Patients: 33 patients with PNCS/EAS with intense/severe hypercortisolism.

10-year comparative follow up of familial versus multifactorial chylomicronemia syndromes

Manon Belhassen, Eric Van Ganse, Maeva Nolin, Marjorie Bérard, Hanane Bada, Eric Bruckert, Michel Krempf, Vinciane Rebours, René Valéro & Philippe Moulin
The relative incidence of acute pancreatitis, ischemic cardiovascular disease and diabetes in hyperchylomicronemic patients exhibiting familial chylomicronemia syndrome (FCS), or multifactorial chylomicronemia syndrome (MCS), is unknown. The objective was to study the occurrence of these events in FCS and MCS patients compared with the general population. Twenty-nine FCS and 124 MCS patients, with genetic diagnosis, in four lipid clinics were matched with 413 controls. Individual hospital data linked to the national claims database were collected...

Registration Year

  • 2022
    3
  • 2021
    2
  • 2019
    1

Resource Types

  • Dataset
    6

Affiliations

  • Hospices Civils de Lyon
    6
  • Centre Hospitalier Universitaire de Bordeaux
    3
  • Cancer Center of Lyon
    3
  • Marseille Public University Hospital System
    1
  • Dokuz Eylül University
    1
  • University of Newcastle Australia
    1
  • University of Rennes 1
    1
  • University of Alberta
    1
  • Hospital Universitario Virgen Macarena
    1
  • Centre Hospitalier Universitaire de Toulouse
    1